10/541058A Yong Chu 8-10-2007

$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:22:14 ON 10 AUG 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:22:32 ON 10 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2007 HIGHEST RN 944380-35-2
DICTIONARY FILE UPDATES: 9 AUG 2007 HIGHEST RN 944380-35-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10541058\10541058.str





chain nodes :
7 8 9 10 11 13 14 15 17 19 20 26 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 16 21 22 23 24 25
chain bonds :
1-14 2-20 3-19 4-7 5-15 6-17 7-8 7-13 8-9 8-10 8-11 15-16 21-30 22-29
23-26 24-32 25-31 26-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-21 16-25 21-22 22-23 23-24 24-25
exact/norm bonds :
2-20 3-19 4-7 5-15 6-17 7-8 7-13 8-9 8-10 8-11 15-16 21-30 22-29 23-26
24-32 25-31 26-28
exact bonds :
1-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-21 16-25 21-22 22-23 23-24 24-25

G1:H,CH3

G2:H,CH3,CH2,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS 19:CLASS 20:CLASS
21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H,Me
G2 H,Me,CH2,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:23:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 173 TO 747
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:24:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 582 TO ITERATE

100.0% PROCESSED 582 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 173.00 173.21

FILE 'CAPLUS' ENTERED AT 09:24:16 ON 10 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Aug 2007 VOL 147 ISS 8
FILE LAST UPDATED: 9 Aug 2007 (20070809/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3
L4          24 L3

=> s l4 and inflammatory
         184109 INFLAMMATORY
            337 INFLAMMATORIES
         184213 INFLAMMATORY
                   (INFLAMMATORY OR INFLAMMATORIES)
L5          15 L4 AND INFLAMMATORY

=> s l4 and analgesic
          44577 ANALGESIC
          45637 ANALGESICS
          59964 ANALGESIC
                   (ANALGESIC OR ANALGESICS)
L6           3 L4 AND ANALGESIC

=> s l5 and l6
L7           2 L5 AND L6

=> d ibib abs tot

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:1039706  CAPLUS  Full-text
DOCUMENT NUMBER:         146:92565
TITLE:                   Plasma and synovial fluid concentrations of nimesulide
                         and its main metabolite after a single or repeated
                         oral administration in patients with knee
                         osteoarthritis
AUTHOR(S):               Blanchi, M.; Ferrario, P.; Balzarini, P.; Broggini, M.
CORPORATE SOURCE:        Department of Pharmacology, Faculty of Medicine,
                         University of Milan, Milan, Italy
SOURCE:                  Journal of International Medical Research (2006),
                         34(4), 348-354
                         CODEN: JIMRBV; ISSN: 0300-0605
```

PUBLISHER: Cambridge Medical Publications Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of this study was to evaluate plasma and synovial fluid concns. of the non-steroidal anti-inflammatory drug nimesulide and its major metabolite (hydroxynimesulide, M1), after a single 100 mg dose of nimesulide and a repeated (14 day) administration, 100 mg twice a day, in patients with osteoarthritis of the knee and joint effusion. Nimesulide was rapidly absorbed in plasma and distributed in synovial fluid. On day 1, effective concns. were present 30 min after the first dose and on day 14, the synovial fluid concn. of nimesulide was significantly higher than that measured on day 1; no accumulation was obsd. in plasma. After 14 days of treatment, both the plasma and synovial fluid concns. of M1 were significantly higher than those measured on day 1. These data may help to explain the rapid onset of the analgesic effect of nimesulide demonstrated in several clin. conditions, including painful osteoarthritis.
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:204424 CAPLUS Full-text
DOCUMENT NUMBER: 137:226148
TITLE: A randomized, crossover, assessor-blind study of the pharmacokinetics of parenteral nimesulide versus placebo in healthy Indian volunteers
AUTHOR(S): Gogtay, N. J.; Mhatre, R.; Dalvi, S. S.; Desai, S.; Gupta, A.; Kshirsagar, N. A.
CORPORATE SOURCE: Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Bombay, India
SOURCE: Clinical Drug Investigation (2002), 22(1), 17-23
CODEN: CDINFR; ISSN: 1173-2563
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The pharmacokinetics of nimesulide (1 mg/kg) were studied after i.m. administration to healthy Indian volunteers. The tolerability of the formulation vs. that of placebo (vehicle only) was also detd. The i.m. route was used to obtain rapid onset of action. Safety was measured by pre- and postdrug biochem. investigations, ECG and phys. examn., while tolerability was assessed by pain as perceived by the subject. The pharmacokinetics of nimesulide and its metabolite 4-hydroxynimesulide were calcd. by measuring max. plasma concn. (Cmax), time to reach Cmax (tmax), area under the concn. vs. time curve from time zero to 48 h (AUC0-48) and from time zero to infinity (AUC0-.infin.), clearance and vol. of distribution. The 1-mg/kg dose gave a mean Cmax of 2.36 mg/L, and tmax was 2.73 h. The AUC0-48 was 22.57 .mu.g.bul.h/mL and AUC0-.infin. was 23.96 .mu.g.bul.h/mL. For the 4-hydroxynimesulide metabolite, Cmax was 0.76 mg/L and tmax was 5.04 h. All 13 subjects experienced pain at the injection site of the, while 12 of 13 subjects had pain when receiving placebo. This difference was not significant. Parenteral nonsteroidal anti-inflammatory drugs have shown good analgesic efficacy in general surgery coupled with the advantage of an opioid-sparing effect. The 1 mg/kg dose of this nimesulide formulation can be used as the starting dose for Phase II clin. studies.
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:204424 CAPLUS Full-text
DOCUMENT NUMBER: 137:226148
TITLE: A randomized, crossover, assessor-blind study of the pharmacokinetics of parenteral nimesulide versus placebo in healthy Indian volunteers
AUTHOR(S): Gogtay, N. J.; Mhatre, R.; Dalvi, S. S.; Desai, S.; Gupta, A.; Kshirsagar, N. A.
CORPORATE SOURCE: Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Bombay, India
SOURCE: Clinical Drug Investigation (2002), 22(1), 17-23
CODEN: CDINFR; ISSN: 1173-2563
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The pharmacokinetics of nimesulide (1 mg/kg) were studied after i.m. administration to healthy Indian volunteers. The tolerability of the formulation vs. that of placebo (vehicle only) was also detd. The i.m. route was used to obtain rapid onset of action. Safety was measured by pre- and postdrug biochem. investigations, ECG and phys. examn., while tolerability was assessed by pain as perceived by the subject. The pharmacokinetics of nimesulide and its metabolite 4-hydroxynimesulide were calcd. by measuring max. plasma concn. (Cmax), time to reach Cmax (tmax), area under the concn. vs. time curve from time zero to 48 h (AUC0-48) and from time zero to infinity (AUC0-.infin.), clearance and vol. of distribution. The 1-mg/kg dose gave a mean Cmax of 2.36 mg/L, and tmax was 2.73 h. The AUC0-48 was 22.57 .mu.g.bul.h/mL and AUC0-.infin. was 23.96 .mu.g.bul.h/mL. For the 4-hydroxynimesulide metabolite, Cmax was 0.76 mg/L and tmax was 5.04 h. All 13 subjects experienced pain at the injection site of the, while 12 of 13 subjects had pain when receiving placebo. This difference was not significant. Parenteral nonsteroidal anti-inflammatory drugs have shown good analgesic efficacy in general surgery coupled with the advantage of an opioid-sparing effect. The 1 mg/kg dose of this nimesulide formulation can be used as the starting dose for Phase II clin. studies.

IT 109032-22-6, 4-Hydroxynimesulide
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)
(nimesulide and its hydroxy metabolite pharmacokinetics in humans)

RN 109032-22-6 CAPLUS
CN Methanesulfonamide, N-[2-(4-hydroxyphenoxy)-4-nitrophenyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.47	195.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'REGISTRY' ENTERED AT 09:33:56 ON 10 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2007 HIGHEST RN 944380-35-2
DICTIONARY FILE UPDATES: 9 AUG 2007 HIGHEST RN 944380-35-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s l4 and cyclohexylamine
          6009 CYCLOHEXYLAMINE
L8           0 L4 AND CYCLOHEXYLAMINE

=> s cyclohexylamine
L9        6009 CYCLOHEXYLAMINE

=> s l9 and l4
L10          0 L9 AND L4

=> file caplus
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.60	208.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

FILE 'CAPLUS' ENTERED AT 09:37:48 ON 10 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2007 VOL 147 ISS 8
FILE LAST UPDATED: 9 Aug 2007 (20070809/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> d l6 ibib abs tot

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1039706 CAPLUS Full-text
DOCUMENT NUMBER: 146:92565
TITLE: Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis
AUTHOR(S): Blanchi, M.; Ferrario, P.; Balzarini, P.; Broggini, M.
CORPORATE SOURCE: Department of Pharmacology, Faculty of Medicine, University of Milan, Milan, Italy
SOURCE: Journal of International Medical Research (2006), 34(4), 348-354
CODEN: JIMRBV; ISSN: 0300-0605
PUBLISHER: Cambridge Medical Publications Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of this study was to evaluate plasma and synovial fluid concns. of the non-steroidal anti-inflammatory drug nimesulide and its major metabolite (hydroxynimesulide, M1), after a single 100 mg dose of nimesulide and a repeated (14 day) administration, 100 mg twice a day, in patients with osteoarthritis of the knee and joint effusion. Nimesulide was rapidly absorbed in plasma and distributed in synovial fluid. On day 1, effective concns. were present 30 min after the first dose and on day 14, the synovial fluid concn. of nimesulide was significantly higher than that measured on day 1; no accumulation was obsd. in plasma. After 14 days of treatment, both the plasma and synovial fluid concns. of M1 were significantly higher than those measured on day 1. These data may help to explain the rapid onset of the analgesic effect of nimesulide demonstrated in several clin. conditions, including painful osteoarthritis.
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:204424 CAPLUS Full-text
DOCUMENT NUMBER: 137:226148
TITLE: A randomized, crossover, assessor-blind study of the pharmacokinetics of parenteral nimesulide versus placebo in healthy Indian volunteers
AUTHOR(S): Gogtay, N. J.; Mhatre, R.; Dalvi, S. S.; Desai, S.; Gupta, A.; Kshirsagar, N. A.
CORPORATE SOURCE: Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Bombay, India

SOURCE: Clinical Drug Investigation (2002), 22(1), 17-23
CODEN: CDINFR; ISSN: 1173-2563
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The pharmacokinetics of nimesulide (1 mg/kg) were studied after i.m. administration to healthy Indian volunteers. The tolerability of the formulation vs. that of placebo (vehicle only) was also detd. The i.m. route was used to obtain rapid onset of action. Safety was measured by pre- and postdrug biochem. investigations, ECG and phys. examn., while tolerability was assessed by pain as perceived by the subject. The pharmacokinetics of nimesulide and its metabolite 4-hydroxynimesulide were calcd. by measuring max. plasma concn. (Cmax), time to reach Cmax (tmax), area under the concn. vs. time curve from time zero to 48 h (AUC0-48) and from time zero to infinity (AUC0-.infin.), clearance and vol. of distribution. The 1-mg/kg dose gave a mean Cmax of 2.36 mg/L, and tmax was 2.73 h. The AUC0-48 was 22.57 .mu.g.bul.h/mL and AUC0-.infin. was 23.96 .mu.g.bul.h/mL. For the 4-hydroxynimesulide metabolite, Cmax was 0.76 mg/L and tmax was 5.04 h. All 13 subjects experienced pain at the injection site of the, while 12 of 13 subjects had pain when receiving placebo. This difference was not significant. Parenteral nonsteroidal anti-inflammatory drugs have shown good analgesic efficacy in general surgery coupled with the advantage of an opioid-sparing effect. The 1 mg/kg dose of this nimesulide formulation can be used as the starting dose for Phase II clin. studies.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1974:108186 CAPLUS Full-text
DOCUMENT NUMBER: 80:108186
TITLE: (Sulfonamido)diphenyl ethers
PATENT ASSIGNEE(S): Riker Laboratories Inc.
SOURCE: Ger. Offen., 37 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2333643	A1	19740124	DE 1973-2333643	19730702
US 3840597	A	19741008	US 1972-268606	19720703
ZA 7303807	A	19740424	ZA 1973-3807	19730605
NL 7308661	A	19740107	NL 1973-8661	19730621
ES 416223	A1	19760901	ES 1973-416223	19730623
SE 417089	B	19810223	SE 1973-8862	19730625
SE 417089	C	19810611		
FI 61877	B	19820630	FI 1973-2024	19730625
FI 61877	C	19821011		
CA 1009663	A1	19770503	CA 1973-175343	19730629
BE 801812	A1	19740102	BE 1973-133036	19730702
FR 2190460	A1	19740201	FR 1973-24207	19730702
JP 49042640	A	19740422	JP 1973-74666	19730702
JP 58050984	B	19831114		
DD 110262	A5	19741212	DD 1973-172003	19730702
AU 7357586	A	19750109	AU 1973-57586	19730702
AT 7305834	A	19751015	AT 1973-5834	19730702
AT 330740	B	19760712		
GB 1435755	A	19760512	GB 1973-31454	19730702

CH 585705	A5	19770315	CH 1973-9611		19730702
CH 586667	A5	19770415	CH 1976-10327		19730702
HU 168676	B	19760628	HU 1973-RI512		19730703
PL 90016	B1	19761231	PL 1973-163799		19730703
AT 7500791	A	19760215	AT 1975-791		19750203
AT 332862	B	19761025			
ES 440989	A1	19770701	ES 1975-440989		19750916
JP 57136560	A	19820823	JP 1982-831		19820106
JP 58035989	B	19830805			
JP 57140712	A	19820831	JP 1982-830		19820106
JP 59031755	A	19840220	JP 1982-153797		19820903
JP 59044311	B	19841029			
PRIORITY APPLN. INFO.:			US 1972-268606	A	19720703
			US 1970-28148	A2	19700413
			US 1971-118476	A2	19710224
			AT 1973-5834	A	19730702

GI For diagram(s), see printed CA Issue.

AB About 30 ethers [I, Rn = 4- or 5-O2N or -H2N, 5,4-Cl(O2N), 5,4-Cl(H2N), 5,4-MeO(O2N), or 4,6-(O2N)2; R1 = H, Me, Et, Bu, Ac, or SO2Me; R2 = H, F, Cl, or Me; R3m = H, 4-Cl, 4-Me, 4-MeO, or 2,4-Cl2] or their salts with HCl or Et3N were prepd. and useful as analgesics, antipyretics, herbicides, inflammation inhibitors, and microbicides. Thus, 4,2-O2N(H2N)C6H3OPh reacted with MeSO2Cl in pyridine to give 4,2-O2N(MeSO2NH)C6H3OPh. 2,4-Br(O2N)C6H3NHSO2Me reacted with PhOH in pyridine and C6H6 with H2O removal at .ltoreq.150.degree. to give 5,2-O2N(MeSO2NH)C6H3OPh (II), which was also prepd. from 2-PhOC6R4NHSO2Me by nitration, e.g. with HNO3 in AcOH or with N2O4 in CHCl3. II was treated successively with Na2CO3 and MeI in Me2CO to give 5,2-O2N(MeSO2NMe)C6H3OPh. 5,2-O2N(MeSO2NH)C6H3OC6H4Cl-4 was reduced with H over Pd/C at .apprx.3.16 atm to give 5,2-H2N(MeSO2NH)C6H3OC6H4Cl-4.

```
=> d ibib abs hitstr 3
L10 HAS NO ANSWERS
'IBIB ABS HITSTR ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
          data.  (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
          data.
SDA ----- All Structure DAta (image, attributes, connection table and
          map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIA), SCT, SDA, SIM, SAT, NOS:end

=> d l6 ibib abs hitstr 3

L6   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1974:108186  CAPLUS  Full-text
DOCUMENT NUMBER:          80:108186
TITLE:                    (Sulfonamido)diphenyl ethers
PATENT ASSIGNEE(S):       Riker Laboratories Inc.
SOURCE:                   Ger. Offen., 37 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   4
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2333643	A1	19740124	DE 1973-2333643	19730702
US 3840597	A	19741008	US 1972-268606	19720703
ZA 7303807	A	19740424	ZA 1973-3807	19730605
NL 7308661	A	19740107	NL 1973-8661	19730621
ES 416223	A1	19760901	ES 1973-416223	19730623
SE 417089	B	19810223	SE 1973-8862	19730625
SE 417089	C	19810611		
FI 61877	B	19820630	FI 1973-2024	19730625
FI 61877	C	19821011		
CA 1009663	A1	19770503	CA 1973-175343	19730629
BE 801812	A1	19740102	BE 1973-133036	19730702
FR 2190460	A1	19740201	FR 1973-24207	19730702
JP 49042640	A	19740422	JP 1973-74666	19730702
JP 58050984	B	19831114		
DD 110262	A5	19741212	DD 1973-172003	19730702
AU 7357586	A	19750109	AU 1973-57586	19730702
AT 7305834	A	19751015	AT 1973-5834	19730702
AT 330740	B	19760712		
GB 1435755	A	19760512	GB 1973-31454	19730702
CH 585705	A5	19770315	CH 1973-9611	19730702
CH 586667	A5	19770415	CH 1976-10327	19730702
HU 168676	B	19760628	HU 1973-RI512	19730703
PL 90016	B1	19761231	PL 1973-163799	19730703
AT 7500791	A	19760215	AT 1975-791	19750203
AT 332862	B	19761025		
ES 440989	A1	19770701	ES 1975-440989	19750916
JP 57136560	A	19820823	JP 1982-831	19820106
JP 58035989	B	19830805		
JP 57140712	A	19820831	JP 1982-830	19820106
JP 59031755	A	19840220	JP 1982-153797	19820903
JP 59044311	B	19841029		

PRIORITY APPLN. INFO.:	US 1972-268606	A	19720703
	US 1970-28148	A2	19700413
	US 1971-118476	A2	19710224
	AT 1973-5834	A	19730702

GI For diagram(s), see printed CA Issue.

AB About 30 ethers [I, Rn = 4- or 5-O2N or -H2N, 5,4-Cl(O2N), 5,4-Cl(H2N), 5,4-MeO(O2N), or 4,6-(O2N)2; R1 = H, Me, Et, Bu, Ac, or SO2Me; R2 = H, F, Cl, or Me; R3m = H, 4-Cl, 4-Me, 4-MeO, or 2,4-Cl2] or their salts with HCl or Et3N were prepd. and useful as analgesics, antipyretics, herbicides, inflammation inhibitors, and microbicides. Thus, 4,2-O2N(H2N)C6H3OPh reacted with MeSO2Cl in pyridine to give 4,2-O2N(MeSO2NH)C6H3OPh. 2,4-Br(O2N)C6H3NHSO2Me reacted with PhOH in pyridine and C6H6 with H2O removal at .ltoreq.150.degree. to give 5,2-O2N(MeSO2NH)C6H3OPh (II), which was also prepd. from 2-PhOC6R4NHSO2Me by nitration, e.g. with HNO3 in AcOH or with N2O4 in CHCl3. II was treated successively with Na2CO3 and MeI in Me2CO to give 5,2-O2N(MeSO2NMe)C6H3OPh. 5,2-O2N(MeSO2NH)C6H3OC6H4Cl-4 was reduced with H over Pd/C at .apprx.3.16 atm to give 5,2-H2N(MeSO2NH)C6H3OC6H4Cl-4.

IT 51765-76-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 51765-76-5 CAPLUS

CN Methanesulfonamide, N-[2-(4-methoxyphenoxy)-4-nitrophenyl]- (9CI) (CA INDEX NAME)



=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.58	224.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-5.46

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:41:16 ON 10 AUG 2007